Protective effects of COVID-19 vaccination in splenectomized patients with immune thrombocytopenia

Xiang Liu; Xinai Gan; Jing Xu; Yutong Wang; Jie Huang; Xu He; Yan Li; Yuping Gong; Bing Peng; Ting Niu

doi:10.1111/bjh.19405

Protective effects of COVID-19 vaccination in splenectomized patients with immune thrombocytopenia

Br J Haematol. 2024 Apr 17. doi: 10.1111/bjh.19405. Online ahead of print.

Authors

Xiang Liu¹, Xinai Gan^{1

2}, Jing Xu¹, Yutong Wang^{1

2}, Jie Huang¹, Xu He³, Yan Li¹, Yuping Gong¹, Bing Peng⁴, Ting Niu¹

Affiliations

¹ Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
² West China School of Medicine, Sichuan University, Chengdu, China.
³ Department of Hematology, Nanchong Central Hospital, Nanchong, Sichuan, China.
⁴ Department of Hepatopancreatobiliary Surgery, West China Hospital, Sichuan University, Chengdu, China.

PMID: 38632670
DOI: 10.1111/bjh.19405

Abstract

Splenectomy is an effective treatment for immune thrombocytopenia (ITP). The effect of COVID-19 vaccination on splenectomized patients with ITP during the COVID-19 pandemic has not been reported. Therefore, this study aimed to investigate the effect of COVID-19 vaccination on clinical outcomes in these patients. This was a longitudinal study of splenectomized patients with ITP. A total of 191 splenectomized patients were included in this study. After a median follow-up of 114 months, 146 (76.4%) patients had a sustained response to splenectomy. During COVID-19 infection, vaccinated patients showed a lower risk of severe infections (odds ratio [OR], 0.13; 95% confidence interval [CI]: 0.05-0.36; p < 0.001), hospitalization (OR, 0.13; 95% CI, 0.04-0.48; p = 0.002), and ITP exacerbation (OR, 0.16; 95% CI, 0.04-0.67; p = 0.012). These findings indicate that COVID-19 vaccination plays a protective role in splenectomized patients with ITP.

Keywords: COVID‐19; immune thrombocytopenia; splenectomy; vaccination.

Abstract

Grants and funding